Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €132.16 EUR
Change Today -0.20 / -0.15%
Volume 0.0
As of 1:35 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

lonza group ag-reg (LO3) Snapshot

Open
€131.88
Previous Close
€132.36
Day High
€132.98
Day Low
€131.77
52 Week High
07/20/15 - €137.23
52 Week Low
08/8/14 - €76.29
Market Cap
7.0B
Average Volume 10 Days
70.7
EPS TTM
--
Shares Outstanding
52.9M
EX-Date
04/10/15
P/E TM
--
Dividend
€2.56
Dividend Yield
1.82%
Current Stock Chart for LONZA GROUP AG-REG (LO3)

Related News

No related news articles were found.

lonza group ag-reg (LO3) Related Businessweek News

View More BusinessWeek News

lonza group ag-reg (LO3) Details

Lonza Group Ltd. supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Specialty Ingredients and Pharma&Biotech. The Specialty Ingredients segment offers consumer care products comprising actives for antidandruff shampoos, and natural and organic cosmetic ingredients; vitamin B compounds; and microbial control solutions, including disinfectants and sanitizers that protect from dangerous and unwanted microbes. This segment also provides custom agricultural manufacturing services to enhance crop yields and food quality; industrial Solutions, including preservatives and biocide blends; products and services that enhance the quality of wood; and sanitizers and other treatment chemicals for pools, spas, water parks, as well as in the treatment of surface waters for drinking, agriculture, irrigation, food processing, and industrial applications. The Pharma&Biotech segment develops and manufactures active pharmaceutical ingredients (APIs) for drug companies; microbial parenteral API, including antibody fragments, vaccines, cytokines, plasmid DNA, fusion proteins, and PEGylated products; and chemical custom services, such as chemically derived active ingredients, peptide syntheses, antibody drug conjugates, cytotoxic, and small organic molecules. It also offers cell culture, transfection, and molecular biology tools for life-science research; media used in the production of therapeutics; endotoxin detection assays; and products and services targeting cardiovascular, respiratory, neurological, metabolic, cancer, and other disease research areas. This segment serves customers in academic and government institutions, and in biotech and pharmaceutical organizations. Lonza Group Ltd. was founded in 1897 and is headquartered in Basel, Switzerland.

9,721 Employees
Last Reported Date: 07/22/15
Founded in 1897

lonza group ag-reg (LO3) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.1.3M
Compensation as of Fiscal Year 2014.

lonza group ag-reg (LO3) Key Developments

Lonza Group Ltd. Announces Agreement with TAP Biosystems Group plc

Lonza Group Ltd. has reached an agreement with TAP Biosystems Group plc to distribute the company's Real Architecture For 3D Tissue, or RAFT, 3D cell culture system. The RAFT System uses a patented absorber technology to create cell layers in high-density collagen that mimic the in vivo environment. This system enables researchers to generate more biologically meaningful data from their cell culture studies. The versatile RAFT Kit is available in a number of formats and is appropriate for analysis using a wide variety of imaging, biochemical and histological techniques. In combination with Lonza's human primary cells and media solutions, the RAFT 3D Cell Culture System empowers researchers to create physiologically relevant cell culture models for use across drug discovery and research applications. The RAFT 3D Cell Culture System has been designed with simple, easy-to-follow protocols that allow researchers to set up 3D cell cultures in under an hour. The RAFT Kit includes a collagen type I solution and biocompatible absorbers, which remove the medium from cell-seeded collagen hydrogels and allow researchers to control both cell concentration and matrix density. RAFT 3D Cell Culture System is a flexible system that supports a variety of formats including 24-well, 96-well and insert-well. The key differentiation of the RAFT System from other platforms is its versatility. This system can be utilized with one cell type, or multiple cell types in parallel. Cells can be cultured within the collagen scaffold, or on top, or both. The addition of permeable membrane cell culture inserts provides other extensions to the system, allowing the generation of barrier models including air-lift models. Furthermore, the system is compatible with a variety of cell types and has already been used to successfully generate 3D cultures in a number of research areas, including oncology, toxicology and neuroscience.

Lonza Group Ltd. and Octane Biotech Inc. to Evaluate Octane Cocoon Cell Production Platform

Lonza Group Ltd. and Octane Biotech Inc. have agreed to enter into an exclusive technology evaluation of the Octane Cocoon cell production platform for personalized cell therapy manufacturing. Unlike current, labor-intensive production methods, the Octane Cocoon has the potential to enable the automated manufacturing of patient-specific cell therapies for maximum efficiency, traceability and scale-up. Under the terms of the agreement, Lonza will evaluate the Octane Cocoon platform for autologous cell therapy products.

Lonza Group Ltd Signs New Long-Term Product Supply Agreement with Alexion

Lonza Group Ltd. announced the signing of a new long-term product supply agreement with Alexion. Under the agreement Lonza will construct and launch a new suite dedicated to Alexion manufacturing. Lonza will own and operate the suite as part of its Portsmouth, NH (USA) site. This contract is an expansion of an existing manufacturing agreement. This agreement will supplement existing production of Alexion products at multiple Lonza facilities. The expansion of the existing site in Portsmouth, near Boston, MA (USA), will provide valued customers increased access to Lonza's proven biological manufacturing and regulatory expertise, experienced global workforce and high level of focused customer service. Lonza has more than two decades of worldwide manufacturing experience with mammalian biotherapeutics.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LO3:GR €132.16 EUR -0.20

LO3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ashland Inc $114.32 USD +0.02
Clariant AG SFr.19.28 CHF +0.33
Croda International PLC 3,040 GBp +52.00
Owens Corning $44.85 USD +0.65
PerkinElmer Inc $52.92 USD +1.50
View Industry Companies
 

Industry Analysis

LO3

Industry Average

Valuation LO3 Industry Range
Price/Earnings 34.2x
Price/Sales 1.9x
Price/Book 3.6x
Price/Cash Flow 34.5x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LONZA GROUP AG-REG, please visit www.lonza.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.